Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Gregory D. Gorgas will represent the company, with an on-demand presentation available to registered attendees starting September 9 at 7:00 AM Eastern Time.
The presentation will be accessible via webcast on the conference platform and Artelo's investor relations website. Management will also engage in one-on-one meetings with qualified investors throughout the conference. Artelo focuses on modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatologic and neurological conditions.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ARTL declined 3.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
Artelo’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 AM Eastern Time. A webcast of the Company’s presentation can also be accessed at https://journey.ct.events/view/e83ca657-746a-443a-9769-d1e1a38009c4 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact ARTL@crescendo-ir.com.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
When is Artelo Biosciences (ARTL) presenting at the H.C. Wainwright Global Investment Conference?
Where can investors access Artelo Biosciences' (ARTL) presentation for the H.C. Wainwright conference?
What is the focus of Artelo Biosciences' (ARTL) research and development?
How can investors request a meeting with Artelo Biosciences (ARTL) management at the H.C. Wainwright conference?
